Adaptimmune Therapeutics PLC - - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ADAP Nasdaq 8731 https://www.adaptimmune.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adaptimmune Therapeutics PLC -

Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma - Jan 9th, 2023 1:00 pm
Even after rising 48% this past week, Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are still down 72% over the past five years - Jan 8th, 2023 12:06 pm
Mesa Labs and Eldorado Gold have been highlighted as Zacks Bull and Bear of the Day - Dec 28th, 2022 11:51 am
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Dec 27th, 2022 2:05 pm
Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma - Dec 23rd, 2022 6:20 pm
Hedge funds investors may adopt severe steps after Adaptimmune Therapeutics plc's (NASDAQ:ADAP) latest 20% drop adds to a year losses - Dec 10th, 2022 2:02 pm
Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent - Nov 18th, 2022 1:00 pm
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP) - Nov 13th, 2022 12:28 pm
Lab notes: Adaptimmune to reduce workforce; NRx completes $11M debt financing - Nov 11th, 2022 3:52 pm
Adaptimmune Therapeutics Third Quarter 2022 Earnings: Beats Expectations - Nov 10th, 2022 11:03 am
Why Adaptimmune Therapeutics Stock Is Glowing Green Today - Nov 8th, 2022 8:11 pm
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business - Nov 8th, 2022 2:41 pm
Adaptimmune Reports Third-Quarter Financial Results and Business Update - Nov 8th, 2022 12:30 pm
Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers - Nov 8th, 2022 12:00 pm
Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022 - Oct 27th, 2022 4:27 pm
GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day - Oct 25th, 2022 3:12 pm
Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK - Oct 25th, 2022 12:00 pm
Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers - Sep 9th, 2022 2:23 pm
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors - Sep 9th, 2022 11:00 am
Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials - Aug 25th, 2022 12:00 pm